Edwards Lifesciences (EW) Expected to Announce Earnings on Thursday

Edwards Lifesciences (NYSE:EW) is expected to be announcing its Q2 2026 results after the market closes on Thursday, July 23rd. Analysts expect the company to announce earnings of $0.73 per share and revenue of $1.7002 billion for the quarter. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Individuals can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 23, 2026 at 5:00 PM ET.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same period in the prior year, the firm posted $0.64 EPS. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. On average, analysts expect Edwards Lifesciences to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Edwards Lifesciences Stock Performance

Shares of EW opened at $85.05 on Tuesday. The business’s fifty day simple moving average is $87.50 and its two-hundred day simple moving average is $83.91. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a market cap of $48.97 billion, a price-to-earnings ratio of 45.24, a P/E/G ratio of 2.15 and a beta of 0.86.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $91.70, for a total transaction of $56,762.30. Following the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,671,117.80. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 45,577 shares of company stock worth $3,855,527. Company insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the third quarter valued at about $25,000. Kemnay Advisory Services Inc. purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $27,000. Rakuten Securities Inc. raised its stake in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares during the period. Kelleher Financial Advisors bought a new stake in Edwards Lifesciences during the 3rd quarter valued at approximately $50,000. Finally, Chapman Financial Group LLC purchased a new position in Edwards Lifesciences in the 2nd quarter worth approximately $63,000. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on EW. Robert W. Baird increased their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Truist Financial boosted their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Citigroup raised their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Finally, Royal Bank Of Canada raised their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $98.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.